Jessica Hergert

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Rafael Santana-Davila, MD, discusses the introduction of immunotherapy and lurbinectedin to the SCLC armamentarium, as well as areas in need of additional research.

Patrick I. Borgen, MD, highlights the effects of the coronavirus disease 2019 (COVID-19) pandemic on the field of oncology.

The addition of the histone deacetylase inhibitor vorinostat to the mTOR inhibitors sirolimus or everolimus demonstrated encouraging clinical activity and manageable safety in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

A fixed-duration of venetoclax plus rituximab led to sustained and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia who achieved undetectable minimal residual disease.

Gagandeep Brar, MD, discusses how the treatment paradigm has expanded in hepatocellular carcinoma, continuing sequencing challenges, and ongoing trials that are expected to impact the landscape.

Philip W. Kantoff, MD, discusses the evolving treatment landscape of mCRPC, the early efficacy data demonstrated with VERU-111, and other emerging areas of research that are poised to impact the prostate cancer paradigm.

New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and benefits of both approaches.

Caroline Billingsley, MD, spoke to established and emerging treatment modalities in ovarian cancer and the successes and pitfalls of key clinical trials of antibody-drug conjugates and immunotherapy in this space.

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

The presence of RAS/CBL mutations was found to be associated with adverse phenotypic features and survival outcomes in patients with myelofibrosis.

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

First-line treatment with the combination of nivolumab and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma versus chemotherapy alone.

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.

The combination of nivolumab and ipilimumab demonstrated improved responses in a cohort of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer compared with a cohort of chemotherapy-exposed patients.

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Kartik Konduri, MD, discussed current treatment options that are available for patients with ALK, ROS1, and RET–positive NSCLC, as well as promising agents in the pipeline.

Aarthi Shenoy, MD, discusses how the emergence of the antibody-drug conjugate, brentuximab vedotin, has had a positive impact on improving overall survival and progression-free survival for patients with T-cell lymphomas and classical Hodgkin lymphoma.

The coronavirus disease 2019 has had a significant impact on cancer care and created widespread challenges for health care systems across the globe.

David R. Spigel, MD, discusses the IMpower110, CYPRESS-1, and CANOPY-A trials, and spoke to the potential future outlook of drug development in NSCLC.

David A. Braun, MD, PhD, discusses findings from a pooled analysis of 3 clinical trials evaluating the potential impact of immunophenotypes, somatic mutations, and chromosomal alterations on response to PD-1 inhibition and recurrence in patients with renal cell carcinoma.

Huma Q. Rana, MD, MPH, discusses a recent trial aimed to identify how genetic counseling could impact an individual’s decision to undergo genetic testing and ultimately, identify strategies to improve access to this service for men with potentially lethal prostate cancer.